- Benefits on adherence and HbA1c to be
validated in a real-world setting -
PARIS, Sept. 13, 2016 /CNW/ - Sanofi announced today
that adults with type 2 diabetes treated with Toujeo®
(insulin glargine 300 Units/mL) experienced a consistently lower
rate of confirmed or severe hypoglycemia both at night and at any
time of the day compared with those treated with Lantus®
(insulin glargine 100 Units/mL), at all levels of HbA1c
(average blood glucose over the previous three months) achieved at
month 6. The results of this new patient-level meta-analysis from
the EDITION 1, 2 and 3 Phase 3 clinical trials in patients with
type 2 diabetes were presented at the 52nd Annual
Meeting of the European Association for the Study of Diabetes
(EASD) in Munich, Germany.
"For people with diabetes, it is vital to achieve good
glycemic control in order to minimize the risk of microvascular
complications. Risk of hypoglycemia can be an important factor in
the person as well as their treating physician's attitude towards
treatment of their diabetes, and can lead to improved adherence and
reduced glycemic control in real-world conditions," said
Pratik Choudhary, Senior Lecturer
and Consultant in Diabetes, Kings
College London, UK and lead
author of the presentation. "These results show that in
more than 2,000 patients that Toujeo could enable adults
with type 2 diabetes to achieve equivalent glycemic control with
less hypoglycemia vs. Lantus. We look forward to the validation of
these important findings in real-world settings."
In addition, the first clinical evidence in a real life setting
to reflect the possibility of achieving glycemic control with fewer
hypoglycemic events was presented at the American Diabetes
Association (ADA) 76th Scientific Sessions. Those data
were drawn from existing patient-level information (from the
Predictive Health Intelligence Environment database) on patients
switching to Toujeo from other basal insulins under real-life
conditions. The results demonstrated that patients treated with
Toujeo experienced a mean estimated reduction in HbA1c
of 0.64% (p<0.0001) after 6 months of treatment, while the
occurrence of hypoglycemia was 6.0% at baseline and 5.1% at
follow-up.
"These encouraging meta-analysis findings, in
combination with preliminary patient-level data
from a real-life setting, provide
useful information about Toujeo's potential to help people with
diabetes achieve better glycemic control without additional risk of
hypoglycemia," said Riccardo
Perfetti, Head of Global Diabetes Medical Team, Sanofi.
"We are currently conducting a broad real-world
clinical program to confirm these findings."
Sanofi is conducting three large, randomized clinical trials -
ACHIEVE, REACH and REGAIN CONTROL - evaluating in real-life
conditions the effect of Toujeo in people with type 2 diabetes.
These trials will provide an important evaluation of the
effectiveness of Toujeo's disease-management strategy, that could
be particularly relevant to healthcare professionals, diabetes
educators and payers.
About EASD abstract
The meta-analysis was performed on patient-level data from the
EDITION 1, 2 and 3 phase 3 clinical trials (n=2,103). Annualized
rate of confirmed (≤3.9 mmol/L or ≤70.2 mg/dL) or severe
hypoglycemia rate (events per participant-year) was correlated with
HbA1c data at month 6 for each patient, using a negative
binomial regression model. There was no overlap between the curves
for Toujeo® (insulin glargine 300 Units/mL) and
Lantus® (insulin glargine 100 Units/mL), demonstrating
that the hypoglycemia rate was lower with Toujeo® than
with Lantus® at all levels of HbA1c.
The presentation is titled: "Hypoglycaemia as a function of
HbA1c in type 2 diabetes (T2DM): insulin glargine 300 U/ml in a
patient-level meta-analysis of EDITION 1, 2 and 3" (Choudhary
P, et al. Oral presentation #10, European Association for the Study
of Diabetes (EASD) 52nd Annual Meeting, Munich, Germany, September 13, 2016).
About patient-level information from the PHIE
database
Adults with type 2 diabetes who had used other basal insulins
within the 6 months prior to Toujeo initiation (one or more
prescription orders of Toujeo® between March 2015 and December
2015) were identified. The PHIE records of those identified
(n=881) were assessed for HbA1c and incidence of
confirmed (≤3.9 mmol/L or ≤70.2 mg/dL) or severe hypoglycemia up to
6 months prior to and up to 6 months after initiation.
Among the subpopulation of patients (n=267) with
HbA1c measured at baseline and during follow-up (0-6
months), mean HbA1c was 8.97% at baseline and 8.33% at
follow-up. For the subpopulation of patients (n=449) with
occurrence of hypoglycemia reported at baseline and during
follow-up (0-3 months), this was 6.0% at baseline and 5.1% at
follow-up.
The poster is titled "Real-World Assessment of Patient
Characteristics and Clinical Outcomes of Early Users of the New
Insulin Glargine 300U/mL" (Ye F, et al. Poster presentation
943-P, New Orleans, LA, U.S.,
Saturday, June 11, 2016).
About ACHIEVE, REACH and REGAIN CONTROL
The ACHIEVE CONTROL study will evaluate the effect of
Toujeo® versus other basal insulins in a real-life
setting on achieving individualized glycemic targets without
hypoglycemia at any time of day in 3,270 uncontrolled insulin-naïve
people in the U.S. with type 2 diabetes.
The REACH CONTROL will follow 920 insulin-naïve people with type
2 diabetes in Europe, comparing
HbA1c change with Toujeo® versus other basal
insulins, alongside incidence of hypoglycemia, change in body
weight, and measures of persistence with treatment and need for
treatment intensification in a real-life setting.
The REGAIN CONTROL study will compare HbA1c
reduction, incidence of hypoglycemia, change in body weight and
persistence with treatment on Toujeo® versus other basal
insulins in 800 people with type 2 diabetes in Europe, who are currently uncontrolled on
basal insulin in a real-life setting. In addition to clinical
measures, the studies will also collect patient feedback on
treatment satisfaction and their experience of hypoglycemia, along
with healthcare resource utilization.
About Toujeo®
Toujeo® is a once-daily basal insulin based on a
broadly-used molecule (insulin glargine). Toujeo has been approved
by the U.S. Food and Drug Administration (FDA), the European
Commission, Health Canada, the Therapeutic Goods Administration in
Australia, and the MHLW in
Japan (where its approved brand
name is Lantus® XR), and is under review by other
regulatory authorities around the world.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs.
Sanofi is organized into five global business units: Diabetes and
Cardiovascular, General Medicines and Emerging Markets, Sanofi
Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in
Paris (EURONEXT: SAN) and in
New York (NYSE: SNY).
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product
development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words "expects", "anticipates",
"believes", "intends", "estimates", "plans"
and similar expressions. Although Sanofi's management believes that
the expectations reflected in such forward-looking statements are
reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic
alternatives, Sanofi's ability to benefit from external
growth opportunities and/or obtain regulatory clearances, risk
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, the impact
of cost containment initiatives and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in
Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by
applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.
SOURCE SANOFI